Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics DENVER, May 18, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development…


Previous articleThe Impact of Specific Genes on Cannabis Use Disorder
Next articlePT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety